Share your insights

Help us by sharing what content you've recieved in your exams


Leukaemia

Background Knowledge 🧠

Definition

  • Leukaemia is a group of cancers that originate in the bone marrowΒ and result in the overproduction of abnormal white blood cells.
  • These abnormal cells interfere with normal blood cell production and function.
  • Leukaemia can be classified into acute and chronic forms, as well as lymphoid or myeloid lineages.

Epidemiology

  • Approximately 9,900 new cases of leukaemia each year in the UK.
  • Acute leukaemias are more common in children, while chronic leukaemias are more common in adults.
  • Slight male predominance.
  • Higher incidence in developed countries.
  • Risk increases with age.

Aetiology and Pathophysiology

  • Genetic mutations and chromosomal abnormalities are key factors.
  • Risk factors: Radiation exposure, certain chemicals (e.g., benzene), prior chemotherapy.
  • Some hereditary conditions (e.g., Down syndrome) increase risk.
  • Pathophysiology involves the clonal expansion of malignant haematopoietic stem cells.
  • These cells proliferate uncontrollably and fail to mature, leading to bone marrow failure.

Types

  • Acute Lymphoblastic Leukaemia (ALL): Common in children, rapid progression.
  • Acute Myeloid Leukaemia (AML): More common in adults, rapid progression.
  • Chronic Lymphocytic Leukaemia (CLL): Common in older adults, slow progression.
  • Chronic Myeloid Leukaemia (CML): Characterised by the Philadelphia chromosome, slow progression initially.
  • Other rare types: Hairy cell leukaemia, T-cell prolymphocytic leukaemia.

Clinical Features 🌑️

Symptoms

  • Fatigue and weakness.
  • Fever and recurrent infections.
  • Bleeding and bruising easily.
  • Bone and joint pain.
  • Weight loss and night sweats.
  • Lymphadenopathy and splenomegaly in chronic forms.

Signs

  • Pallor and signs of anaemia.
  • Petechiae and purpura.
  • Hepatosplenomegaly.
  • Lymphadenopathy.
  • Signs of infection (e.g., oral thrush, pneumonia).
  • Bone tenderness on palpation.

Investigations πŸ§ͺ

Investigations

  • Full blood count: Anaemia, leukocytosis or leukopenia, thrombocytopenia.
  • Peripheral blood smear: Presence of blasts in acute leukaemia.
  • Bone marrow biopsy: Hypercellularity with increased blasts.
  • Cytogenetic analysis: Detect chromosomal abnormalities (e.g., Philadelphia chromosome in CML).
  • Immunophenotyping: Determine lineage of leukaemic cells.
  • Molecular testing: Identify specific mutations (e.g., FLT3 in AML).

Management πŸ₯Ό

Management

  • Acute leukaemia: Immediate treatment with chemotherapy.
  • Chronic leukaemia: Watchful waiting or targeted therapy (e.g., imatinib for CML).
  • Bone marrow or stem cell transplant in eligible patients.
  • Supportive care: Blood transfusions, antibiotics for infections.
  • Radiotherapy for specific indications (e.g., CNS involvement).
  • Palliative care in advanced cases.

Complications

  • Infections due to immunosuppression.
  • Bleeding and bruising due to thrombocytopenia.
  • Anaemia and associated symptoms.
  • Tumour lysis syndrome during treatment.
  • Secondary malignancies.
  • Organ infiltration by leukaemic cells.

Prognosis

  • Varies widely depending on type and stage at diagnosis.
  • ALL has a high cure rate in children with appropriate treatment.
  • CML has a good prognosis with targeted therapy (e.g., imatinib).
  • AML prognosis depends on age, genetic mutations, and response to treatment.
  • CLL often follows an indolent course, but prognosis can worsen with certain genetic mutations.
  • Regular follow-up is crucial for monitoring response to treatment and detecting recurrence.

Key Points

  • Leukaemia is a diverse group of blood cancers with varying prognoses.
  • Early diagnosis and treatment are crucial for improving outcomes.
  • Management includes chemotherapy, targeted therapy, and supportive care.
  • Bone marrow or stem cell transplant may be necessary in some cases.
  • Follow-up care is essential to monitor for complications and recurrence.
  • Research is ongoing to improve treatment options and outcomes for patients with leukaemia.

No comments yet πŸ˜‰

Leave a Reply